Buy Modified GRF (1-29) & Ipamorelin Peptide Blend

Name: Buy Modified GRF (1-29) & Ipamorelin Peptide Blend - Planex Supplies
SKU: Modified GRF (1-29)
Price: 81.00 USD
Availability: InStock

$81.00

Buy the premium Modified GRF (1-29) & Ipamorelin Peptide Blend from Planex Supplies. This advanced dual-action research formulation combines a highly stable, tetra-substituted GHRH analog with a highly selective growth hormone secretagogue (GHS). Together, they are engineered to evaluate synergistic neuroendocrine axis pulsatility, gastrointestinal smooth muscle contractility, and pancreatic beta-cell insulin pathways. Every batch is independently USA-tested with transparent, documented Certificates of Analysis (COAs) to guarantee standard-setting laboratory integrity.

SKU: Modified GRF (1-29) Category: Peptide Blends

Description
Reviews (0)

Advanced Dual-Pathway Neuroendocrine & Gastrointestinal Research Blend

The Modified GRF (1-29) & Ipamorelin Peptide Blend from Planex Supplies combines two distinct molecular structures widely studied for their synergistic influence on endogenous growth hormone (GH) cascades. While Modified GRF 1-29 targets the Growth Hormone-Releasing Hormone (GHRH) receptor pathway, Ipamorelin acts as a highly specific pentapeptide agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a). Operating through complementary secondary messenger pathways, this blend provides a non-competitive model for investigating amplified somatotroph cell responses and downstream metabolic signaling.

Comprehensive Technical Specifications:

Modified GRF 1-29 (Mod GRF 1-29 / Tetra-Substituted GHRH Analog)

Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight: 3367.95 g/mol
Sequence: H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂

Ipamorelin (Selective Ghrelin Receptor Agonist)

Molecular Formula: C₃₈H₄₉N₉O₅
Molecular Weight: 711.86 g/mol
Sequence: Aib-His-D-2Nal-D-Phe-Lys-NH₂

Key Areas of Scientific Research & Complementary Mechanisms:

Enzymatic Durability & Structural Optimization: Standard GRF (1-29) features a rapid half-life that restricts its experimental utility. Modified GRF 1-29 features four key amino acid substitutions (at the 2nd, 8th, 15th, and 27th positions) engineered to prevent dipeptidyl peptidase-4 (DPP-4) degradation, amide hydrolysis, and methionine oxidation. These technical refinements maximize compound stability, allowing for long-term observations of pulsatile growth hormone and Insulin-Like Growth Factor 1 (IGF-1) cell proliferation profiles.
Gastrointestinal Motility & Inflammatory Remediation: High circulating growth hormone levels are studied for their potential to alleviate symptoms of short bowel syndrome and inflammatory bowel disease by interacting with Vasoactive Intestinal Peptide (VIP) receptors like VIPC1. Concurrently, Ipamorelin interacts directly with localized ghrelin receptors in the gut. Preclinical post-surgical models suggest Ipamorelin counteracts the smooth muscle contractile inhibition caused by abdominal intervention, significantly accelerating delayed gastric emptying and restoring acetylcholine responses.
Ischemic Cardiomyocyte Protection: In cardiovascular and myocardial infarction (MI) models, growth hormone secretagogues are evaluated for their cytoprotective capabilities. By activating GHS-R1a, these compounds have been observed to generate positive inotropic effects on ischemic heart tissue. This protective mechanism is hypothesized to preserve or recover phospholamban (p-PLB) levels and sarcoplasmic reticulum calcium content, mitigating ischemia-reperfusion injuries and reducing post-MI tissue scarring.
Skeletal Homeostasis & Glycemic Regulation: In skeletal research models, Ipamorelin has demonstrated an ability to mitigate steroid-induced bone loss. Real-time DXA and mid-diaphyseal pQCT metrics indicate that the peptide targets osteoblasts to enhance cellular proliferation and specialization, leading to up to a four-fold increase in cortical bone mineral content (BMC) and cross-sectional density. Additionally, secretagogues are monitored for pancreatic islet interaction, where they may stimulate insulin release from beta-cells via intracellular calcium channels.

The Planex Supplies Quality Standard

At Planex Supplies, we maintain absolute transparency to preserve the clinical integrity of your scientific research. Our Modified GRF (1-29) + Ipamorelin blend is synthesized to precise laboratory tolerances and verified through high-performance liquid chromatography (HPLC). Every single batch is independently tested within the United States and backed by documented Certificates of Analysis (COAs) to verify molecular concentration.

Verified Purity: ≥ 99% purity guaranteed through mass spectrometry and HPLC profiling.
USA Vetted: Independent laboratory confirmation ensures absolute consistency and freedom from cross-contaminants.
Research Use Only: This compound is synthesized exclusively for in vitro laboratory experimentation and preclinical evaluation. Make sure to double-check the physical label to confirm this information.